These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
5. Statistical perspective on adjusting for center effect in a 2 x 2 crossover design with application to clinical trials. Yue LQ J Biopharm Stat; 2000 Nov; 10(4):559-71. PubMed ID: 11104393 [TBL] [Abstract][Full Text] [Related]
6. Practical Bayesian design and analysis for drug and device clinical trials. Hobbs BP; Carlin BP J Biopharm Stat; 2008; 18(1):54-80. PubMed ID: 18161542 [TBL] [Abstract][Full Text] [Related]
8. The AB/BA crossover: past, present and future? Senn S Stat Methods Med Res; 1994 Dec; 3(4):303-24. PubMed ID: 7889225 [TBL] [Abstract][Full Text] [Related]
9. A Bayesian predictive strategy for an adaptive two-stage design in phase II clinical trials. Sambucini V Stat Med; 2010 Jun; 29(13):1430-42. PubMed ID: 20099246 [TBL] [Abstract][Full Text] [Related]
10. Alternative approaches to the analysis of binary and categorical repeated measurements. Kenward MG; Jones B J Biopharm Stat; 1992; 2(2):137-70. PubMed ID: 1300210 [TBL] [Abstract][Full Text] [Related]
11. Frequentist performance of Bayesian inference with response-adaptive designs. Lecoutre B; Derzko G; Elqasyr K Stat Med; 2010 Dec; 29(30):3219-31. PubMed ID: 21170916 [TBL] [Abstract][Full Text] [Related]
12. CrossOver: an algorithm for the construction of efficient cross-over designs. John JA; Russell KG; Whitaker D Stat Med; 2004 Sep; 23(17):2645-58. PubMed ID: 15316948 [TBL] [Abstract][Full Text] [Related]
13. Statistics and the relationship of clinical research to clinical practice. Khuder SA; Kahaleh B J Rheumatol; 2009 Feb; 36(2):219-20. PubMed ID: 19208555 [No Abstract] [Full Text] [Related]
14. Bayesian assessment of the influence and interaction conditions in multipopulation tailoring clinical trials. Millen BA; Dmitrienko A; Song G J Biopharm Stat; 2014; 24(1):94-109. PubMed ID: 24392980 [TBL] [Abstract][Full Text] [Related]
15. A Bayesian approach to subgroup identification. Berger JO; Wang X; Shen L J Biopharm Stat; 2014; 24(1):110-29. PubMed ID: 24392981 [TBL] [Abstract][Full Text] [Related]
16. A Bayesian approach on sample size calculation for comparing means. Wang H; Chow SC; Chen M J Biopharm Stat; 2005; 15(5):799-807. PubMed ID: 16078386 [TBL] [Abstract][Full Text] [Related]
17. Bayesian decision-theoretic group sequential clinical trial design based on a quadratic loss function: a frequentist evaluation. Lewis RJ; Lipsky AM; Berry DA Clin Trials; 2007; 4(1):5-14. PubMed ID: 17327241 [TBL] [Abstract][Full Text] [Related]
18. A hybrid Bayesian-frequentist approach to evaluate clinical trial designs for tests of superiority and non-inferiority. Shao Y; Mukhi V; Goldberg JD Stat Med; 2008 Feb; 27(4):504-19. PubMed ID: 17854052 [TBL] [Abstract][Full Text] [Related]
19. Bayesian analyses of two-treatment crossover studies. Grieve AP Stat Methods Med Res; 1994 Dec; 3(4):407-29. PubMed ID: 7889229 [TBL] [Abstract][Full Text] [Related]
20. Design and analysis of crossover trials for absorbing binary endpoints. Nason M; Follmann D Biometrics; 2010 Sep; 66(3):958-65. PubMed ID: 19930189 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]